What is Vascular Solutions Earnings Yield (Joel Greenblatt) %?
Vascular Solutions's Enterprise Value for the quarter that ended in Sep. 2016 was $806.6 Mil.
Vascular Solutions's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 was $13.4 Mil. Vascular Solutions's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2016 was 1.66%.
The historical rank and industry rank for Vascular Solutions's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
VASC's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.205 * Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Vascular Solutions's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2016 was 0.89%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Vascular Solutions Earnings Yield (Joel Greenblatt) % Historical Data
The historical data trend for Vascular Solutions's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vascular Solutions's Earnings Yield (Joel Greenblatt) %
For the Medical Devices subindustry, Vascular Solutions's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vascular Solutions's Earnings Yield (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vascular Solutions's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Vascular Solutions's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Vascular Solutionss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2015 is calculated as
Vascular Solutions's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.4 Mil.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Vascular Solutions Earnings Yield (Joel Greenblatt) % Related Terms
Thank you for viewing the detailed overview of Vascular Solutions's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.
Vascular Solutions (Vascular Solutions) Business Description
Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Company's products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Company's products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VASC has been successfully added to your 